Stock Ratings / Health Care / EYPT / forecast

PRPO (38) RPID (47) HBIO (44) BNGO (36) ⌘ Pro Terminal →

EyePoint Inc. (EYPT) 12-Month Stock Forecast & Price Target Cone

Q: What is EYPT's 12-month stock price target?

EyePoint Inc. (EYPT) carries a 12-month consensus base price target of $0.35 (-7.9% from $0.38), with a bull-case target of $20.07 and a bear-case floor of $0.27.

Q: Is EYPT stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates EYPT D- (Sell — SELL) with an RQD Confidence score of 38/100.

$0.38 +0.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.38

EyePoint Inc. (EYPT) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $32.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.38 (-0.07%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-7.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EYPT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY EYPT SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (34% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.40-12.1% Next Q

Q2 (-2Q)

Grade D$2.99-86.6% Next Q

Q3 (-1Q)

Grade D$0.40-5% Next Q

Current

Grade D-$0.38-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EYPT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EYPT currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.21) and Max Pain ($0.40) forces dealer call-delta covering toward $20.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EYPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EYPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your EYPT Position Size: $10,000

Shares at $0.38: 26315.8 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.27

$7,105

$-2,895 (-28.9%)

12M Consensus BaseTarget $0.35

$9,211

$-789 (-7.9%)

12M Bull Case BreakoutTarget $20.07

$528,158

+$518,158 (+5181.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$0	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$19	69%	B
JP MorganUS Large-Cap Research	SELL	$0	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EYPT)

✓Walkthrough of EYPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EYPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -97.12%▼ DESCENDING CHANNEL

2026-10-30O $0.37H $0.38L $0.34C $0.38VOL 6.10M

RES: $12.74SUP: $-2.52SMA50: $3.21SMA200: $10.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EYPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EYPT Butterfly Map → + Track EYPT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -27.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EYPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EYPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EYPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EYPT)

Health Care Rank #724 of 1016 ⚔️ PRPO vs EYPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EYPT vs. PRPO, RPID, HBIO, BNGO)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, EyePoint Inc. (EYPT) ranks #724 by composite RQD confidence (38/100, grade D-) and #793 by equity capitalization ($32.8M). Within this direct 5-issuer industry benchmark cohort, EYPT leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with EYPT at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EYPT ACTIVE EyePoint Inc.	D-	38/100	—	—	-35.0%	+0.69%	$32.8M	Benchmark Subject
PRPO Precipio Inc.	D-	38/100	—	44.2%	-7.9%	+3.59%	$34.6M	/prpo-vs-eypt →
RPID Rapid Micro Biosystems Inc. (Class A)	D	47/100	—	—	-35.0%	-1.37%	$39.6M	/rpid-vs-eypt →
HBIO Harvard Bioscience Inc.	D	44/100	—	57.7%	-35.0%	+4.51%	$40.1M	/hbio-vs-eypt →
BNGO Bionano Genomics Inc.	D-	36/100	—	46.3%	-35.0%	-0.41%	$16.8M	/bngo-vs-eypt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001314102

In its most recent audited fiscal period (FY2025, filed 2025-12-31), EyePoint Inc. (EYPT) reported GAAP revenue of $31.4M (-27.5% vs. FY2024 revenue of $43.3M , and -31.8% cumulative change since FY2023) , GAAP net income of -$232.0M, operating cash flow of -$240.1M, and free cash flow of -$243.4M (-86.8% YoY). On the balance sheet, EYPT closed FY2025 with $364.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$31.4M	-$232.0M	-$240.1M	-$243.4M	$364.0M	—
FY2024 (FY)	2024-12-31	$43.3M	-$130.9M	-$126.2M	-$130.3M	$418.5M	—
FY2023 (FY)	2023-12-31	$46.0M	-$70.8M	$1.9M	$1.9M	—	—

3. EYPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EYPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, EyePoint Inc. (NASDAQ: EYPT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.38 (+0.69% 1D, market cap $32.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EYPT ranks #724 in composite RQD confidence.

How does EYPT compare to PRPO and RPID in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), EYPT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PRPO (Precipio Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -7.9%, cap $34.6M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $39.6M). Among the 5-stock peer group, EYPT leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EYPT?

Per EYPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001314102), EyePoint Inc. generated $31.4M in revenue (-27.5% YoY), -$232.0M in net income, and -$243.4M in free cash flow against $364.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EYPT trading relative to its 50-day, 200-day, and 52-week technical levels?

EYPT last traded at $0.38 (+0.69% on volume of 6,601,742 shares), positioning the stock -88.16% below its 50-day simple moving average ($3.21) and -96.54% below its 200-day simple moving average ($10.98). Across its 52-week range of $0.34 to $19.11, EYPT sits at the 0.2% percentile with a 14-day RSI of 15.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.43).

EYPT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is EYPT's 12-month stock price target?

EyePoint Inc. (EYPT) carries a 12-month consensus base price target of $0.35 (-7.9% from $0.38), with a bull-case target of $20.07 and a bear-case floor of $0.27.

Is EYPT stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates EYPT D- (Sell — SELL) with an RQD Confidence score of 38/100.

Direct Sub-Reports: EYPT RQD Cockpit EYPT 12M Forecast EYPT Earnings & Move EYPT Dividends & DRIP EYPT Insiders & 13F EYPT Whale Options EYPT Profit Sankey EYPT News & Why